Ziopharm Oncology Inc. could raise as much as $63.5 million through an underwritten public offering of 9.6 million shares of common stock priced at $5.75 per share – about 7 percent below Wednesday's closing price – and an underwriter's 30-day option to purchase as many as 1.4 million additional shares.